Search Within

Shanu Modi

  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (8)
Groups
  1. Breast Medicine Service (21)
  2. Department of Medicine (21)
  3. GSK Faculty (21)
  4. Genitourinary Oncology Service (21)
  5. Solid Tumor Oncology Division (21)
  6. Human Oncology and Pathogenesis Program (18)

More Groups

People
  1. David Solit (16)
  2. Clifford Hudis (13)
  3. Sarat Chandarlapaty (8)
  4. Komal Jhaveri (7)
  5. Larry Norton (7)
  6. Neal Rosen (6)

More People

Years
  1. 2021 (1)
  2. 2020 (5)
  3. 2019 (1)
  4. 2018 (1)
  5. 2017 (1)
  6. 2016 (2)

More Years

Publications
  1. Cancer Research (5)
  2. Journal of Clinical Oncology (5)
  3. Breast Cancer Research and Treatment (4)
  4. Clinical Cancer Research (2)
  5. Annals of Oncology (1)
  6. Breast Cancer Research (1)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. American Society of Clinical Oncology (5)
  3. Springer (4)
  4. Biomed Central Ltd (1)
  5. Cell Press (1)
  6. Lippincott Williams & Wilkins (1)

More Publishers

Results (21)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A phase I study
    Journal Article

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S. W.; Slovin, S. F.; Adamow, M.; Blinder, V. S.; Brahmachary, M.; Carlsen, M.; Comen, E.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients
    Meeting Abstract

    Barrios, D. M.; Wang, D. G.; Blinder, V. S.; Bromberg, J.; Drullinsky, P.; Funt, S. A.; Jhaveri, K. L.; Lake, D.; Lyons, T.; Modi, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
    Journal Article

    Wang, D. G.; Barrios, D. M.; Blinder, V. S.; Bromberg, J. F.; Drullinsky, P. R.; Funt, S. A.; Jhaveri, K. L.; Lake, D. E.; Lyons, T.; Modi, S.; more...
    Breast Cancer Research and Treatment (2020)

    Fulltext@MSK | Save
  • The genomic landscape of breast cancer in African American women
    Meeting Abstract

    Serna-Tamayo, C.; Drago, J. Z.; Dos Anjos, C.; Herbert, J.; Pareja, F.; Modi, S.; Jhaveri, K.; Dang, C.; Solit, D. B.; Norton, L.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Genomic profiling of primary and metastatic breast cancer in men
    Meeting Abstract

    Drago, J. Z.; Serna-Tamayo, C.; Dos Anjos, C. H.; Brown, D. N.; Modi, S.; Jhaveri, K.; Solit, D. B.; Traina, T. A.; Chandarlapaty, S.; Reis-Filho, J. S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC)
    Meeting Abstract

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S.; Slovin, S. F.; Blinder, V. S.; Comen, E. A.; Danila, D. C.; Hoffman, D. M. J.; Kang, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • The genomic landscape of endocrine-resistant advanced breast cancers
    Journal Article

    Razavi, P.; Chang, M. T.; Xu, G.; Bandlamudi, C.; Ross, D. S.; Vasan, N.; Cai, Y.; Bielski, C. M.; Donoghue, M. T. A.; Jonsson, P.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Wang, R.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; more...
    Breast Cancer Research (2017)

    Fulltext@MSK | Save
  • Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial
    Meeting Abstract

    Hyman, D. M.; Piha-Paul, S. A.; Rodón, J.; Saura, C.; Puzanov, I.; Shapiro, G. I.; Loi, S.; Joensuu, H.; Hanrahan, A. J.; Modi, S.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save